When producer Kayla Foster called on Anderson to watch a 15-minute short “Your Monster,” he had thoughts. While Tommy Dewey’s performance was impressive as the titular Monster, the makeup ...

The Lincoln Project has billboards at various games around the country over the next two weekends, targeting “disaffected Republicans and undecided independents” in swing states. Today ...

Let us know your top music drop of the week by voting in our poll. By Rania Aniftos Spooky season is wrapping up with Halloweekend, and to celebrate, music fans have a lot of new music to enjoy.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases ...

On Monday, Morgan Stanley (NYSE:MS) initiated coverage on BioAge Labs Inc (NASDAQ:BIOA), assigning the stock an Overweight rating and setting a price target of $40.00. The new rating reflects the ...

On Monday, BioAge Labs Inc (NASDAQ:BIOA) stock received a positive outlook from a major financial institution, as coverage was initiated with a Buy rating and a price target set at $42. The ...

On Monday, Citi initiated coverage on BioAge Labs Inc (NASDAQ:BIOA) shares, giving the biotech company a Buy rating and setting a price target of $45.00. The firm highlighted BioAge's focus on ...

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetration of 15% into the incretin-treated market.